Clinical Trials

Sponsor: SWOG

Sponsor Study ID: S1800D

Study Title: A Phase II/III Study of N 803 (ALT 803) Plus Pembrolizumab Versus Standard of Care in Participants With Stage IV or Recurrent Non Small Cell Lung Cancer Previously Treated With Anti PD 1 or Anti PD L1 Therapy (Lung MAP Non Match Sub Study)

NCT Number: NCT05096663

Phase: II/III

Protocol Type: Treatment

Age Group: Adults

Disease Sites: Lung

Study Objectives: This phase II/III Lung-MAP trial studies how well immunotherapy treatment with N-803 (ALT-803) and pembrolizumab working in treating patients with non-small cell lung cancer that has spread to other places in the body (advanced). Natural killer cells, part of our immune system, are always on alert and ready to defend our bodies from many kinds of infection or rogue cells, such as those that cause cancer. N-803 (ALT-803) may activate natural killer cells so that they can stimulate an immune response to help fight cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving N-803 (ALT-803) and pembrolizumab may help shrink and stabilize lung cancer or prevent it from returning.

For more information about the trial above please contact the study team:

Trial opened at the following institutions: Medical University of South Carolina

Study Documents
(MUSC NetID required for document access)